PMID- 22208663
OWN - NLM
STAT- MEDLINE
DCOM- 20120829
LR  - 20221207
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 31
IP  - 1
DP  - 2012 Jan 2
TI  - Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis 
      and angiogenesis in cervical cancer.
PG  - 1
LID - 10.1186/1756-9966-31-1 [doi]
AB  - BACKGROUND: Tissue factor pathway inhibitor-2 (TFPI-2) is an extracellular matrix 
      associated broad-spectrum Kunitz-type serine proteinase inhibitor. Recently, down 
      regulation of TFPI-2 was suggested to be involved in tumor invasion and 
      metastasis in some cancers. METHODS: This study involved 12 normal cervical 
      squamous epithelia, 48 cervical intraepithelial neoplasia (CIN), and 68 cervical 
      cancer. The expression of TFPI-2, Ki-67 and vascular endothelial growth factor 
      (VEGF) were investigated by immunohistochemistry staining. The apoptolic 
      index(AI) was determined with an in situ end-labeling assay(TUNEL). And the 
      marker of CD34 staining was used as an indicator of microvessel density (MVD). 
      RESULTS: TFPI-2 expression has a decreasing trend with the progression of 
      cervical cancer and was significantly correlated with FIGO stage, lymph node 
      metastasis and HPV infection. In addition, there were significant positive 
      correlations between the grading of TFPI-2 expression and AI(P=0.004). In 
      contrast, the expression of TFPI-2 and VEGF or MVD was negatively correlated 
      (both p < 0.001). However, we did not establish any signi fi cant correlation 
      between Ki-67 and TFPI-2 expression in cervical cancer. CONCLUSIONS: The results 
      suggested that the expression of TFPI-2 had a decreasing trend with tumor 
      progression of cervical cancer. There was a close association between the 
      expression of TFPI-2 and tumor cell apoptosis and angiogenesis in patients with 
      cervical cancer. TFPI-2 may play an inhibitive role during the development of 
      cervical cancer.
FAU - Zhang, Qiao
AU  - Zhang Q
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, Shenyang, 110004, China.
FAU - Zhang, Yao
AU  - Zhang Y
FAU - Wang, Shi Z
AU  - Wang SZ
FAU - Wang, Ning
AU  - Wang N
FAU - Jiang, Wei G
AU  - Jiang WG
FAU - Ji, Yao H
AU  - Ji YH
FAU - Zhang, Shu L
AU  - Zhang SL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120102
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Glycoproteins)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (tissue-factor-pathway inhibitor 2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apoptosis/*genetics
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Glycoproteins/*genetics/*metabolism
MH  - Humans
MH  - Ki-67 Antigen/genetics/metabolism
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/genetics/metabolism
MH  - Uterine Cervical Neoplasms/blood supply/genetics/*metabolism/pathology
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
MH  - Uterine Cervical Dysplasia/blood supply/genetics/*metabolism/pathology
PMC - PMC3314549
EDAT- 2012/01/03 06:00
MHDA- 2012/08/30 06:00
PMCR- 2012/01/02
CRDT- 2012/01/03 06:00
PHST- 2011/09/30 00:00 [received]
PHST- 2012/01/02 00:00 [accepted]
PHST- 2012/01/03 06:00 [entrez]
PHST- 2012/01/03 06:00 [pubmed]
PHST- 2012/08/30 06:00 [medline]
PHST- 2012/01/02 00:00 [pmc-release]
AID - 1756-9966-31-1 [pii]
AID - 10.1186/1756-9966-31-1 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2012 Jan 2;31(1):1. doi: 10.1186/1756-9966-31-1.